These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Thrombocytosis and anaemia in women with recurrent ovarian cancer prior to a second-line chemotherapy.
    Author: Nather A, Mayerhofer K, Grimm C, Hefler L, Leodolter S, Obermair A, Joura EA.
    Journal: Anticancer Res; 2003; 23(3C):2991-4. PubMed ID: 12926151.
    Abstract:
    BACKGROUND: To investigate the incidence and the prognostic value of platelet count and serum haemoglobin (Hb) in patients with recurrent ovarian cancer prior to second-line chemotherapy. MATERIALS AND METHODS: Clinical records were reviewed for 31 patients with recurrent ovarian cancer. Survival analysis was evaluated by univariate (Kaplan-Meier product limit method and log-rank test) analysis. We analysed the results for the overall survival. Anaemia and thrombocytosis were defined as a serum Hb level < 12 g/dl and as platelet count > 300,000/microL, respectively. RESULTS: Thrombocytosis and tumour anaemia were present in 55% and 42% of the patients, respectively. Tumour anaemia was of no prognostic value with respect to overall survival in our series. In patients with thrombocytosis, the median survival rate was reduced (p = 0.05). CONCLUSION: Our data suggest that a platelet count > 300,000/microL appears to be an adverse prognostic parameter in patients with recurrent ovarian cancer prior to a second-line chemotherapy.
    [Abstract] [Full Text] [Related] [New Search]